info@synchemia.com | sales@synchemia.com 
9766925136 
Custom Products & Intermediate
Intermediate and Custom Synthesis Manufacturing Services
At Synchemia Research Chemical, we specialize in providing high-quality intermediate and custom synthesis manufacturing services tailored to meet the unique needs of our clients. Whether you require synthesis of complex intermediates or custom synthesis of specialty compounds, peptide Synthesis, we are committed to delivering reliable solutions with a focus on quality and efficiency
- Synthesis of intermediate compounds for pharmaceutical and chemical applications.
- Custom synthesis of specialty chemicals based on client specifications.
- Process optimization and scale-up capabilities.
(E)-N-Methylcinnamylamine
| CAT No | SRC-INT-065 |
| CAS No | 83554-67-0 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
(S)-2-((tert-butoxycarbonyl)amino)-5-ethoxy-5-oxopentanoic acid
| CAT No | SRC-INT-066 |
| CAS No | 65487-73-2 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
2-Chlorobenzo[D] Oxazole
![2-Chlorobenzo[D] Oxazole](https://synchemia.com/upload/intermediates/SRC-INT-067.png)
| CAT No | SRC-INT-067 |
| CAS No | 615-18-9 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
N-(2,6-dimethylphenyl)-2-methoxy-N-methylacetamide
| CAT No | SRC-INT-068 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
4-Acetamido-3-chlorophenyl Acetate
| CAT No | SRC-INT-069 |
| CAS No | 60144-85-6 |
| API/END USE | Intermediates |
| COA | Download File |
| INV STATUS | IN STOCK |
N-[(8-tert-butyl-1,4-dioxaspiro[4.5]decan-3-yl) methyl]-N-propan-1-amine
![N-[(8-tert-butyl-1,4-dioxaspiro[4.5]decan-3-yl) methyl]-N-propan-1-amine](https://synchemia.com/upload/intermediates/SRC-INT-070.png)
| CAT No | SRC-INT-070 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
2-methoxyethyl 4-(propylamino)benzoate
| CAT No | SRC-INT-071 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)pentan-2-ol
| CAT No | SRC-INT-072 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
3-butyl-6-chloro-1-methyl-1H-indol
| CAT No | SRC-INT-073 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
2-Prop-2-enylcyclopentane-1,3-dione
| CAT No | SRC-INT-074 |
| CAS No | 67136-10-1 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
3-butyl-7-chloro-1-methyl-1H-indole
| CAT No | SRC-INT-075 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
N-Propan-2-yl-glycine
| CAT No | SRC-INT-076 |
| CAS No | 3338-25-5 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
Methyl 3-((2-((tert-butoxycarbonyl)(phenyl)amino)-4-chlorophenyl)amino)-3-oxopropanoate
| CAT No | SRC-INT-077 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
4-((tert-butoxycarbonyl)amino)pyridine 1-oxide
| CAT No | SRC-INT-078 |
| CAS No | NA |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
(R)-1-(2,3-dimethylphenyl)ethanol
| CAT No | SRC-INT-079 |
| CAS No | 1659319-50-2 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
(R)-2-(1-hydroxyethyl)benzonitrile
| CAT No | SRC-INT-080 |
| CAS No | 1076195-46-4 |
| API/END USE | Intermediates/Impurity Standard |
| COA | Download File |
| INV STATUS | IN STOCK |
Let’s advance your research together.
Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.
